Florence, Jan. 16, 2024 – PQE Group has concluded the fiscal year 2023 with a remarkable 10% growth, surpassing 100 million euros in revenues. As a preferred advisor to pharma manufacturing, medical device corporations, and SMEs worldwide, PQE Group’s success is attributed to its resilience, adaptability, and strategic vision in navigating the complex global landscape.
Resilience and Innovation Amidst Global Challenges
“In a time of geopolitical challenges, crises, and inflation rates, PQE Group stands out for its resilience and ability to thrive in uncertain times, showcasing positive growth across all financial indicators,” stated Gilda D’Incerti, CEO & Founder of PQE Group. The success is rooted in meticulous planning, strategic investments in cutting-edge technologies, and a corporate culture that values agility and innovation.
Optimizing Operations and Pioneering Growth
In the preceding fiscal year, PQE Group made substantial strides in prioritizing process optimization and executing strategic digital investments. Building on the extraordinary 68% surge in revenue achieved in 2022 compared to the previous year, the company undertook a robust reorganizational strategy throughout 2023. This initiative strategically positioned PQE Group at the pinnacle of efficiency, with a pivotal catalyst for the enhanced net revenue margin being the company’s steadfast commitment to process efficiency. This commitment acted as a catalyst for a significant phase of innovation, solidifying PQE Group’s reputation as an industry leader.
Revolutionizing Clinical Research and Expanding Globally
This commitment to innovation is epitomized by the establishment of ReSQ-Up, PQE Group’s internal Contract Research Organization (CRO). ReSQ-Up is dedicated to fostering collaborations with companies, hospitals, start-ups, and research institutes in conducting groundbreaking clinical trials for innovative products. The CRO introduces a revolutionary paradigm in clinical research, focusing specifically on women’s health and exploring the applications of therapeutic cannabis.
Simultaneously, PQE Group undertook a strategic global expansion by inaugurating new offices in Canada, Saudi Arabia, Ireland, and Singapore. This expansion has increased the total number of offices to 46 worldwide, accompanied by the establishment of 26 legal entities. This deliberate and strategic move aims to fortify PQE Group’s presence and connections in burgeoning markets, with a special focus on Southeast Asia. The global expansion serves as a testament to PQE Group’s commitment to staying at the forefront of industry trends and meeting the evolving needs of its diverse clientele.
Commitment to Sustainability
Stefano Carganico, Chief Innovation Officer at PQE Group, emphasized the company’s commitment to sustainability. Strategic investments in digital solutions and eco-friendly choices resulted in a reduction of 900 trips within a year, equivalent to traveling three times around the world. This not only enhances efficiency but also contributes to environmental protection.
“After years of hyper growth and consolidation, we have set our sights on more ambitious and long-term goals, incorporating sustainability into our strategic process,” noted Carganico. “In just six months, we improved profitability, trimming unnecessary costs and redirecting resources to improve our offerings and penetrate key markets.”
Conclusion: A Beacon of Success in Life Science Consulting
PQE Group’s remarkable growth and strategic initiatives position the company as a beacon of success in the Life Science consulting sector. Their ability to thrive amidst global challenges while maintaining a strong commitment to innovation and sustainability sets PQE Group apart in the industry.
